Atorvastatin/CoenzymeQ10 in Congestive Heart Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01925937|
Recruitment Status : Unknown
Verified August 2013 by Amin Nemati, Isfahan University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : August 20, 2013
Last Update Posted : August 20, 2013
|Condition or disease||Intervention/treatment||Phase|
|Congestive Heart Failure||Drug: Atorvastatin Drug: Coenzyme Q10 Drug: placebo for coenzyme Q10||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||January 2014|
Experimental: Coenzyme Q10 & Atorvastatin
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
|Drug: Atorvastatin Drug: Coenzyme Q10|
Active Comparator: Atorvastatin & placebo
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
|Drug: Atorvastatin Drug: placebo for coenzyme Q10|
- Change in cardiac Ejection Fraction (EF) [ Time Frame: Baseline for the first time and after 4 months for the second time ]For the determination of change in EF,cardiac EF was determined two times . Baseline :at the beginning of study(before intervention) and the second time after 4 months(after intervention).
- Change in New York Heart Association Function Class [ Time Frame: Baseline for the first time and after 4 months for the second time ]For the determination of change in New York Heart Association Function Class.it was determined two times .Baseline:at the beginning of study(before intervention)and the second time after 4 months(after intervention).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925937
|Contact: Amin Nemati, MDfirstname.lastname@example.org|
|Iran, Islamic Republic of|
|Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran||Recruiting|
|Isfahan, Iran, Islamic Republic of, 8174673461|
|Contact: Amin Nemati, MD 00989131009918 email@example.com|
|Principal Investigator: Javad Shahabi, MD|
|Study Director:||Masoud Pourmoghaddas, cardiologist||Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.|